18F-FDG PET-CT分期局限期滤泡性淋巴瘤的根治性放疗:ILROG协作研究
国际淋巴瘤放射肿瘤学组(ILROG)多中心回顾性研究纳入512例经PET-CT分期、接受单纯放疗的I-II级1-3A期滤泡性淋巴瘤患者,中位随访52个月,5年无进展生存率为68.9%、总生存率为95.7%,I期无进展生存率74.1%优于II期49.1%(P<.0001)。
要点
- PET-CT分期后单纯放疗的5年无进展生存率为68.9%、总生存率为95.7%。
- I期患者5年无进展生存率74.1%,高于II期的49.1%(P<.0001)。
- 多因素分析显示II期(HR 2.11)和BCL2表达(HR 1.62)与较差无进展生存显著相关。
核心结论
- PET-CT分期患者放疗后的结局似乎优于既往系列,尤其在I期疾病中,提示放疗对真正局限期滤泡性淋巴瘤的治愈潜力被低估。
研究设计与样本
- 国际淋巴瘤放射肿瘤学组(ILROG)指导下的多中心回顾性研究,纳入2000年至2017年间16个中心共512例患者。
- 纳入标准为:未经治疗的I-II期滤泡性淋巴瘤(1-3A级)、单纯放疗且剂量等效≥24 Gy、经PET-CT分期、年龄≥18岁、随访≥3个月。
- 中位年龄58岁(范围20-90),410例(80.1%)为I期,中位放疗剂量30 Gy(范围24-52),中位随访52个月(范围3.2-174.6)。
主要发现
- 5年无进展生存率为68.9%,5年总生存率为95.7%。
- I期5年无进展生存率为74.1%,II期为49.1%(P<.0001)。
- 8例(1.6%)发生野内复发,4例(0.8%)发生边缘复发,局部控制率为97.6%。
- 多因素分析中,II期(HR 2.11;95%CI 1.44-3.10)和BCL2表达(HR 1.62;95%CI 1.07-2.47)与较差的无进展生存显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiotherapy (RT) can be curative in patients with localized follicular lymphoma (FL), with historical series showing a 10-year disease-free survival of 40 to 50%. As 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography with computerized tomography (PET-CT) upstages 10 to 60% of patients compared to CT, we sought to evaluate outcomes in patients staged by PET-CT, to determine if more accurate staging leads to better patient selection and results. We conducted a multicenter retrospective study under the direction of the International Lymphoma Radiation Oncology Group (ILROG). Inclusion criteria were: RT alone for untreated stage I to II FL (grade 1-3A) with dose equivalent ≥24 Gy, staged by PET-CT, age ≥18 years, and follow-up ≥3 months. End points were freedom from progression (FFP), local control, and overall survival (OS). A total of 512 patients treated between 2000 and 2017 at 16 centers were eligible for analysis; median age was 58 years (range, 20-90); 410 patients (80.1%) had stage I disease; median RT dose was 30 Gy (24-52); and median follow-up was 52 months (3.2-174.6). Five-year FFP and OS were 68.9% and 95.7%. For stage I, FFP was 74.1% vs 49.1% for stage II (P < .0001). Eight patients relapsed in-field (1.6%). Four had marginal recurrences (0.8%) resulting in local control rate of 97.6%. On multivariable analysis, stage II (hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.44-3.10) and BCL2 expression (HR, 1.62; 95% CI, 1.07-2.47) were significantly associated with less favorable FFP. Outcome after RT in PET-CT staged patients appears to be better than in earlier series, particularly in stage I disease, suggesting that the curative potential of RT for truly localized FL has been underestimated.
引用
- Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2018. PMID: 30446493. doi:10.1182/blood-2018-04-843540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。